These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36114896)

  • 21. PHLPP2 is a novel biomarker and epigenetic target for the treatment of vitamin C in pancreatic cancer.
    Chen L; Song H; Luo Z; Cui H; Zheng W; Liu Y; Li W; Luo F; Liu J
    Int J Oncol; 2020 May; 56(5):1294-1303. PubMed ID: 32319585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential target antigens for immunotherapy in human pancreatic cancer.
    Schmitz-Winnenthal FH; Galindo-Escobedo LV; Rimoldi D; Geng W; Romero P; Koch M; Weitz J; Krempien R; Niethammer AG; Beckhove P; Buchler MW; Z'graggen K
    Cancer Lett; 2007 Jul; 252(2):290-8. PubMed ID: 17320278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged survival of a patient affected by pancreatic adenocarcinoma with massive lymphocyte and dendritic cell infiltration after interleukin-2 immunotherapy. Report of a case.
    Nobili C; Degrate L; Caprotti R; Franciosi C; Leone BE; Trezzi R; Romano F; Uggeri F; Uggeri F
    Tumori; 2008; 94(3):426-30. PubMed ID: 18705415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
    Laheru D; Lutz E; Burke J; Biedrzycki B; Solt S; Onners B; Tartakovsky I; Nemunaitis J; Le D; Sugar E; Hege K; Jaffee E
    Clin Cancer Res; 2008 Mar; 14(5):1455-63. PubMed ID: 18316569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
    Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma.
    Salami A; Obaid T; Joshi ART
    Am J Surg; 2019 Jan; 217(1):103-107. PubMed ID: 29807632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional immunotherapy for liver and peritoneal metastases.
    Reha J; Katz SC
    J Surg Oncol; 2017 Jul; 116(1):46-54. PubMed ID: 28543176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
    Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
    Morse MA; Nair SK; Boczkowski D; Tyler D; Hurwitz HI; Proia A; Clay TM; Schlom J; Gilboa E; Lyerly HK
    Int J Gastrointest Cancer; 2002; 32(1):1-6. PubMed ID: 12630764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
    Li J; Yuan S; Norgard RJ; Yan F; Sun YH; Kim IK; Merrell AJ; Sela Y; Jiang Y; Bhanu NV; Garcia BA; Vonderheide RH; Blanco A; Stanger BZ
    Cancer Discov; 2021 Mar; 11(3):736-753. PubMed ID: 33158848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy.
    Atiq S; Atiq OO; Atiq ZO; Samad S; Atiq O
    Cureus; 2021 Feb; 13(2):e13133. PubMed ID: 33728149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics.
    Yan Y; Gao R; Trinh TLP; Grant MB
    Clin Cancer Res; 2017 Oct; 23(20):6363-6373. PubMed ID: 28684632
    [No Abstract]   [Full Text] [Related]  

  • 33. Is targeting autophagy a promising lead to unveil the cloak of invisibility in pancreatic cancer?
    Cayron C; Rigal S; Guillermet-Guibert J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101622. PubMed ID: 33770630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101.
    Costa Neves M; Giakoustidis A; Stamp G; Gaya A; Mudan S
    Cureus; 2015 Dec; 7(12):e435. PubMed ID: 26870619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
    Hu ZI; Hellmann MD; Wolchok JD; Vyas M; Shia J; Stadler ZK; Diaz LA; O'Reilly EM
    J Immunother Cancer; 2018 Nov; 6(1):127. PubMed ID: 30458888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
    Botezatu A; Bleotu C; Nastase A; Anton G; Bacalbasa N; Duda D; Dima SO; Popescu I
    Cancer Genomics Proteomics; 2015; 12(1):21-30. PubMed ID: 25560641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.
    Kunk PR; Bauer TW; Slingluff CL; Rahma OE
    J Immunother Cancer; 2016; 4():14. PubMed ID: 26981244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients.
    MacLean GD; Reddish MA; Longenecker BM
    J Immunother; 1997 Jan; 20(1):70-8. PubMed ID: 9101416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
    Sato N; Parker AR; Fukushima N; Miyagi Y; Iacobuzio-Donahue CA; Eshleman JR; Goggins M
    Oncogene; 2005 Jan; 24(5):850-8. PubMed ID: 15592528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.